Erythema nodosum - a review of an uncommon panniculitis by Blake, Tristan et al.
eScholarship provides open access, scholarly publishing
services to the University of California and delivers a dynamic
research platform to scholars worldwide.
Dermatology Online Journal
UC Davis
Peer Reviewed
Title:
Erythema Nodosum – A Review of an Uncommon Panniculitis
Journal Issue:
Dermatology Online Journal, 20(4)
Author:
Blake, Tristan, The University of Queensland, School of Medicine
Manahan, Melissa, The University of Queensland, School of Medicine, Queensland Institute of
Dermatology
Rodins, Karl, Queensland Institute of Dermatology
Publication Date:
2014
Publication Info:
Dermatology Online Journal
Permalink:
http://escholarship.org/uc/item/2dt0z3mz
Local Identifier:
doj_22376
Abstract:
Panniculitis, inflammation of the subcutaneous fat, is a relatively uncommon condition that usually
presents with inflammatory nodules or plaques. Erythema nodosum (EN) is clinically the most
frequent form of panniculitis and is considered a reactive process that may be triggered by
a wide variety of stimuli. Whilst up to 55% of EN is considered idiopathic, the most common
causes include infections, drugs, systemic illnesses such as sarcoidosis and inflammatory bowel
disease, pregnancy, and malignancy. EN typically presents in the teens and 20s, and is seen
more commonly in females. It is often preceded by a non-specific prodrome of one to three
weeks, which may include fever, malaise, and symptoms of an upper respiratory tract infection.
Cutaneous lesions then follow, typically localized on the extensor aspect of the limbs. The lesions
are painful rounded or oval, slightly raised, non-ulcerative red nodules. The exact pathogenesis
of EN is not understood, although is thought to result from deposition of immune complexes in
the venules of the septae in subcutaneous fat, causing a neutrophilic panniculitis. The classical
histopathological picture is of a septal panniculitis without vasculitis. However, the pathological
features vary with the chronology of the lesions. Even without specific therapy for a causative
condition, EN typically resolves without treatment. Therefore, symptomatic support is adequate
for the majority of patients.
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Abstract 
Panniculitis, inflammation of the subcutaneous fat, is a relatively uncommon condition that usually presents with inflammatory 
nodules or plaques. Erythema nodosum (EN) is clinically the most frequent form of panniculitis and is considered a reactive 
process that may be triggered by a wide variety of stimuli. Whilst up to 55% of EN is considered idiopathic, the most common 
causes include infections, drugs, systemic illnesses such as sarcoidosis and inflammatory bowel disease, pregnancy, and 
malignancy. EN typically presents in the teens and 20s, and is seen more commonly in females. It is often preceded by a non-
specific prodrome of one to three weeks, which may include fever, malaise, and symptoms of an upper respiratory tract infection.  
Cutaneous lesions then follow, typically localized on the extensor aspect of the limbs. The lesions are painful rounded or oval, 
slightly raised, non-ulcerative red nodules. The exact pathogenesis of EN is not understood, although is thought to result from 
deposition of immune complexes in the venules of the septae in subcutaneous fat, causing a neutrophilic panniculitis. The classical 
histopathological picture is of a septal panniculitis without vasculitis.  However, the pathological features vary with the 
chronology of the lesions. Even without specific therapy for a causative condition, EN typically resolves without treatment. 
Therefore, symptomatic support is adequate for the majority of patients. 
Introduction 
Panniculitis, inflammation of the subcutaneous fat, is a relatively uncommon condition that usually presents with inflammatory 
nodules or plaques. A wide variety of subtypes of panniculitis exist, including panniculitis related to infection, external insults, 
malignancy, and inflammatory diseases.  
Erythema nodosum (EN) is clinically the most frequent form of panniculitis and is considered a reactive process that may be 
triggered by a wide variety of stimuli. Whilst up to 55% of EN is considered idiopathic [1], the most common causes include 
infections, drugs, systemic illnesses such as sarcoidosis and IBD, pregnancy, and malignancy (see Table 1 for abbreviations).  EN 
typically presents in the teens and 20s and is seen more commonly in females [1-3]. It is often preceded by a non-specific 
prodrome of one to three weeks, which may include fever, malaise, and symptoms of an upper respiratory tract infection [1-4].  
Cutaneous lesions then follow, typically localized on the extensor aspect of the limbs. The lesions are painful rounded or oval, 
slightly raised, non-ulcerative red nodules [1, 4].  A crop of nodules may last between two to six weeks.  They are self-limiting 
and regress without ulceration, scarring, or atrophy. However EN may recur.  
Table 1. Abbreviation/ Acronyms in this article 
ASOT Antistreptolysin-O titer 
BD Twice daily 
EN Erythema nodosum 
ESR Erythrocyte sedimentation rate 
IBD Inflammatory bowel disease 
NSAIDs Non-steroidal anti-inflammatory drugs 
OD Once daily 
TNF Tumor necrosis factor 
 
Epidemiology 
EN is seen more frequently in females (ratio 5:1) [1, 3] and has a peak incidence between the ages of 18 and 34 years [1, 3, 5, 6]. 
Familial EN has been reported [7], with affected family members showing a common HLA haplotype. The incidence of EN has 
decreased in the antibiotic era, with a current annual incidence of 1 to 5 per 100,000 persons [1, 5, 6]. 
Etiology and Pathogenesis 
EN is likely a delayed hypersensitivity reaction, which can be triggered by a variety of antigens (Table 2) [1-3, 8-13]. Between 
17% and 72% of cases are idiopathic [1-3]. EN is most commonly associated with streptococcal upper respiratory infections; other 
infectious triggers include Yersinia and Mycobacterium tuberculosis [8, 9, 11, 12]. Triggers for EN are suspected to vary with 
location, reflecting the geographical distribution of microbes. In the pediatric demographic, infections predominate (up to 68%) 
[11]. In adults, streptococcal infection usually accounts for 30% of cases. The remaining cases of EN are associated with other 
infections 5–10%, sarcoidosis 10-35%, rheumatological and autoimmune diseases 5%, inflammatory bowel diseases 2–3%, 
medications up to 15% (including oral contraceptives), pregnancy 2%, and rarely malignancy [1-3, 8, 9, 12, 14]. There are many 
single case reports documenting other possible associations, including reports of EN in the setting of vaccinations [15]. 
Table 2. The most common causes of EN in adults 
Drugs 
Oral Contraceptive Pill3,9,12 
Penicillin9,12 
Sulphonamides9,12 
 
Idiopathic1-3, 8, 9, 12, 14 
 
Infections 
Streptococci1,3,8,9,12 
Tuberculosis1, 8,9,11,12 
Upper respiratory tract 
infections1,3,9,12 
Yersiniosis1,3 
 
Pregnancy1,9,12,14 
 
Systemic Illnesses 
Hodgkin’s Lymphoma3,8,9,12 
Inflammatory Bowel 
disease1,3,8,9,12 
Sarcoidosis1,3,8,9,12 
 
 
The exact pathogenesis of EN is not understood, although it is thought that it may be the result of deposition of immune 
complexes in the venules of the septae of subcutaneous fat, causing a neutrophilic panniculitis [16]. A study of ten patients 
showed ‘primed’ neutrophils four times higher than healthy controls [17]. There was also a correlation of primed neutrophils with 
disease activity; however, this may be cause or effect. There may also be a genetic predisposition to EN. In a study that examined 
genetic polymorphisms associated with high TNF-α production in a group of patients with EN, with or without sarcoidosis, there 
was a strong correlation of sarcoidosis-associated EN with TNF αII allele [18].  Furthermore, reports of concurrent Sweet’s 
syndrome and EN have been published and possible etiological and pathogenic associations between the two reactive dermatoses 
have been proposed [19]. 
Clinical Features and Diagnosis 
EN was initially described by Willan in 1798 [20] and was further discussed in 1842 by Wilson, who believed EN to be a type of 
erythema multiforme. In 1860, Hebra went on to describe the clinical manifestations of the condition and suggested ‘dermatitis 
contusiformis’ [21]. 
EN typically manifests with a sudden onset of painful, warm, erythematous, nodules and plaques, typically on the shins, knees, 
and ankles (Figure 1). Lesions may occur at any body site, including the face [1, 22, 23]. The nodules are often more easily 
palpated than visualized and are typically bilateral and symmetrical, ranging between one and five centimeters in diameter. The 
nodules may coalesce to form plaques. In the majority of cases, the lesions become bruise-like and then resolve without scarring 
over a two- to eight-week period. This bruise-like transformation, sometimes known as ‘erythema contusiformis’, is characteristic 
of EN and can be helpful for a retrospective diagnosis [3, 4].  
 
Figure 1. Painful erythematous nodules on the anterior lower legs. 
In addition to the cutaneous symptoms of this disease, prodromal symptoms of fatigue and malaise or symptoms of an upper 
respiratory tract infection may often precede the eruptions by one to three weeks. The clinical picture is that of a nonspecific 
systemic illness, with low-grade fever (60%), malaise (67%), arthralgias (64%), and arthritis (31%) [24]. Pulmonary hilar 
adenopathy may develop as part of the hypersensitivity reaction of EN and is most commonly seen with sarcoidosis, but may be 
seen with other causes too. 
Cases with a classic presentation and evolution typically do not require biopsy because the condition can be confidently diagnosed 
on clinical grounds alone.  A medication history is necessary to rule out drug etiology.  Other forms of panniculitis are the main 
diagnostic consideration on the legs and primary infective processes must be considered at any body site.  Initial evaluation should 
include throat bacterial culture, ASO titer, chest radiograph, tuberculin skin test, and ESR.  Patients with gastrointestinal 
symptoms should have a stool culture. When the etiology is in doubt, infectious serology should be performed for those 
microbiological infections more prevalent in the area. 
The cases that are referred for a specialist dermatologic opinion are more likely to have an atypical clinical appearance or natural 
history.  A biopsy to confirm the diagnosis and rule out other diagnostic possibilities will often be helpful in these cases.   
Some studies from the 1950s through 1980s describe another clinical variant of EN, namely erythema nodosum migrans [25-27]. 
The proposed histopathological and clinical features of this variant are likely observations of classic EN in different stages of 
evolution [28]. A rare form of EN involving a palmoplantar distribution, often unilateral, is seen in children, usually after physical 
activity. There are similar histopathological features to classic EN [29]. 
Histopathology 
The histopathology of EN is quite varied and may require more than one biopsy to sample diagnostic material. Biopsies are 
commonly non-diagnostic owing to poor technique in performing the biopsy or reluctance in taking a large enough biopsy.  
Clinicians are often reluctant to take a large biopsy from inflamed/edematous skin from the lower leg for fear of poor wound 
healing, dehiscence, or poor cosmetic outcome [30]. The best technique is to perform an incisional biopsy extending to the level 
above the fascia.  This technique will provide a specimen that should adequately sample subcutaneous lobules and septa.  A punch 
biopsy will often provide a sample of lower diagnostic yield because a more superficial sample maybe taken and less tissue is 
available for assessment.  
The classical picture is of a septal panniculitis without vasculitis [31–34]. The histologic features of EN can be explained by the 
chronology of lesions [35]. Early lesions demonstrate septal edema and a lymphohistiocytic infiltrate, with an admixture of 
neutrophils and eosinophils. The inflammation is typically concentrated at the periphery of the septae and spreads into 
surrounding fat lobules between adipocytes (Figure 2). There may be edema and lymphocytic infiltration of the walls of veins, 
although the degree of vascular involvement is variable [31-34]. 
   
Figure 2. Widened fibrous septa with spill over into the periphery of lobules 
Figure 3. This septa shows changes of late stage EN with multinucleated giant cells, lymphcytes and an occasional neutrophils. 
Older lesions show fewer vascular changes and a shift from a primarily neutrophilic infiltrate to one of lymphocytes and 
histiocytes (Figure 3).  Histiocytes may display multinucleation or a ‘foam-cell’ appearance.  In some cases, this 
lymphohistiocytic lobular infiltrate may predominate [34].  Septae are widened, with peripheral fibrosis, and inflammation 
extends into the periphery of fat lobules. Miescher’s radial granulomata can also be seen [31-34, 36, 37].  Although characteristic 
of EN, they are also seen in other disorders that might clinically resemble EN, such as erythema induratum, nodular lesions in 
nephrogenic systemic fibrosing dermopathy, Sweet syndrome, and Behçet disease.  
Differential Diagnosis 
The differential diagnosis includes other forms of panniculitis, especially nodular vasculitis, subcutaneous infections owing to 
bacteria or fungi, superficial thrombophlebitis, and cutaneous vasculitides [4, 38-42]. Nodular vasculitis is distinguished from EN 
with involvement of the calves and the presence of ulceration;  it more frequently recurs [43]. However, some authors have 
indicated considerable overlap between the clinical appearances of these entities [13]. Mycobacterium tuberculosis (erythema 
induratum of Bazex) is also a leading cause of nodular vasculitis.  However, it may also be a trigger for EN. A study of 154 
patients with tender cutaneous nodules on the legs by Eimpunth et al [42] showed that inflammatory causes predominate (84.4%; 
panniculitis, vasculitis and granulomas), followed by tumors (6.5%; lymphoma, leukaemia, and leiomyoma), and infections 
(5.8%; mycobacteria and fungal). EN was the most common diagnosis, representing 30.5% of the patients in this case study. The 
authors conclude that histopathological investigation is crucial for a definitive diagnosis in patient with tender leg nodules. 
Treatment 
The evidence for pharmacologic treatment of EN is based almost exclusively on small observational studies.  Hence, the choice of 
agent, dose, and duration is a matter of personal preference.  
Even without specific therapy for a causative condition, EN typically resolves without treatment, therefore symptomatic support is 
adequate for the majority of patients. If there is a treatable, or removable (e.g. medication) cause then this should be addressed; 
rapid resolution is anticipated. Compression bandages and elevation reduce edema and pain. 
NSAIDs such as indomethacin 100mg to 150mg per day or naproxen 250mg BD may be used [44] as an anti-inflammatory and 
for pain relief. Potassium iodide 360–900 mg/day (although not readily available in Australia) may be of benefit [45, 46]. The 
mechanism for potassium iodide in improving EN has not been confirmed. However, potassium iodide has been suggested to 
release heparin from mast cells, suppressing delayed hypersensitivity reactions. Potassium iodide may produce a goiter in utero 
and is contraindicated during pregnancy. Severe hypothyroidism secondary to exogenous intake of iodide has been also been 
described [47]. Most commonly potassium iodide may cause abdominal pain, diarrhea, nausea, and vomiting. Other, less common 
side effects include urticaria and angioedema, swelling of the limbs, face, lips, tongue, throat, and lymph glands [48]. 
Colchicine 2 mg daily for 3 days, then 1 mg daily for 2 to 4 weeks was used more commonly in the past however now is not used 
as frequently for neutrophilic dermatoses [49]. Heparin under occlusion has been suggested as a topical agent [33]. Dapsone 
100mg daily and hydroxychloroquine 200 mg BID are used in chronic or recurrent cases. A brief course of systemic 
corticosteroids is infrequently required and may exacerbate an infectious trigger such as tuberculosis. Intralesional corticosteroids 
may be of benefit for recalcitrant nodules. Recent reports include use of anti-TNF biological agents [50, 51], especially in patients 
with active IBD. However, these are contraindicated in the presence of infections (in particular tuberculosis should be excluded) 
[51]. Case reports suggest that thalidomide and methotrexate may be of benefit. Treatment options during pregnancy should be 
restricted to non-pharmacological means,.However, in cases where this is not sufficient, discussions in conjunction with an 
obstetrician about the risks and benefits of potential drug regimens are recommended [10]. A summary of treatments is depicted in 
Table 3. 
Table 3. Treatments for Erythema Nodosum 
First Line Agents NSAIDs (3) 
Second Line Agents Colchicine (2) 
Potassium iodide (2) (may not be available) 
Topical Agents Heparinoid ointment under occlusion (3) 
Severe Disease Prednisone (3)  
Recalcitrant Nodules Intra-lesional corticosteroid (3)  
Chronic/ Recurrent Disease Dapsone (3) 
Hydroxychloroquine (3)  
Other agents Anti- TNF monoclonal antibodies (3) 
Thalidomide (3) 
Methotrexate (3) 
Level of evidence: 1. double-blind studies; 2. case series; 3. case reports. 
 
Conclusion 
EN is a relatively uncommon dermatological condition found more frequently in younger females. The typical presentation 
consists of painful rounded or oval nodular erythematous lesions on the lower limbs and often follows a non-specific prodromal 
phase. The differential diagnosis includes erythema induratum and cutaneous vasculitis. Streptococcal infections are the most 
common cause identified, but most cases are idiopathic. The diagnosis is usually made clinically without biopsy.  Quality 
evidence for treatment is lacking, although most cases resolve without intervention. Symptom relief is therefore the mainstay of 
treatment of most patients.   
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